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Loss of the short arm of chromosome 1 is a hallmark of oligodendroglial tumours (OTs). Deletion mapping studies in OTs have
revealed multiple commonly deleted regions on chromosome 1p, suggesting that there are more than one tumour suppressor gene.
To map critical deletion regions on 1p, a series of 25 OTs were examined for loss of heterozygosity (LOH) on 19 polymorphic
markers across the 1p arm using microsatellite analysis. Our study revealed that 60% of tumours had LOH of all informative markers
on 1p and identified one tumour showing LOH at telomeric markers only. Since this deletion region lies in one of the critical deletion
intervals defined previously, we then screened another series of 27 OTs specifically at 1p36.3 for LOH using nine polymorphic
markers. A total of 12% (six out of 52) of tumours were found to carry interstitial deletions. The allelic status and the deletion
breakpoints in these tumours with interstitial deletion were further verified by fluorescent in situ hybridisation. The small overlapping
intervals facilitated the delineation of two contiguous minimally deleted regions of 0.76Mb, defined by D1S468 and D1S2845, and of
0.41Mb, bound by D1S2893 and D1S1608, on 1p36.31–36.32. Based on current reference human genome sequence these deletion
regions have been sequenced almost to entirety and contain eight annotated genes. TP73, DFFB and SHREW1 are the only known
genes located in these deletion regions, while the others are uncharacterised novel genes. In conclusion, our study has narrowed
down the critical tumour suppressor loci on 1p36.3, in which two minimally deleted regions are mapped, and markedly reduced the
number of candidate genes to be screened for their involvement in OT development.
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Oligodendroglial tumours (OTs) are primary brain neoplasms that
constitute about 5–18% of all gliomas. These tumours comprise
the classic oligodendrogliomas and mixed oligoastrocytomas. Two
malignancy grades are recognised by the World Health Organiza-
tion (WHO): grade II for the well-differentiated tumours and grade
III for the anaplastic variants (Reifenberger et al, 2000). Unlike
other glioma types, OTs have a unique clinical feature of
remarkable responsiveness to chemotherapy (Macdonald et al,
1990; Perry et al, 1999).
The pathogenesis of OTs is poorly understood. Molecular
studies have shown that allelic deletions of chromosome arms 1p
and 19q are the most frequent genetic alterations in OTs,
suggesting that these chromosomes carry critical tumour suppres-
sor genes and their inactivation is involved in the early stage of OT
development (Bello et al, 1995). The frequencies of allelic loss of 1p
and 19q in OTs are 67–94 and 70–76%, respectively, and of
combined losses is 64–72% (Bello et al, 1995; Bigner et al, 1999;
Husemann et al, 1999; Jeuken et al, 1999; Smith et al, 1999; Iuchi
et al, 2002). Other genetic alterations occurring at lower
frequencies include losses of chromosomes 4, 9, 10, 14, 15 and
18 (Bigner et al, 1999; Jeuken et al, 1999). With regard to target
genes, the CDKN2A tumour suppressor gene located on 9p21 is
found to be homozygously deleted in about 25% of anaplastic
oligodendrogliomas (Cairncross et al, 1998; Bigner et al, 1999;
Watanabe et al, 2001a) and the PTEN gene maps to 10q23 is
mutated in 8% of anaplastic oligodendrogliomas (Sasaki et al,
2001). In addition, recent studies have shown that epigenetic
change also plays an important role in OT formation. Promotor
hypermethylation of RB1 and p14
ARF is detectable, respectively, in
34% (Dong et al, 2001; Watanabe et al, 2001b) and 18–41%
(Watanabe et al, 2001a, Wolter et al, 2001; Alonso et al, 2003) of
OTs. Taken together, these results suggest that at least three
genetic pathways involving CDKN2A/RB1, p14
ARF/p53 and PTEN/
PI3K-AKT are dysregulated in OT development. On contrary, the
target genes from the frequently deleted chromosome arms 1p and
19q are not yet identified.
The majority of OTs harbouring 1p deletion show allelic loss in
all informative markers, indicating that entire or most of short arm
has been deleted. Hence, the deletion breakpoints on 1p have been
derived from a limited number of tumours carrying small deletions
(Reifenberger et al, 1994; Bello et al, 1995; Zhu et al, 1998b;
Husemann et al, 1999; Smith et al, 1999; Iuchi et al, 2002).
Husemann et al (1999) identified two distinct regions of loss from
three OTs carrying interstitial deletions: a distal region between
D1S76 and D1S253 at 1p36.3 (B5Mb) and a proximal region
between D1S482 and D1S2743 (17Mb) at 1p34.2–p36.12. Smith
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yet al (1999) mapped a commonly deleted region to 1p36.31–p36.32
(3.7Mb) between D1S468 and D1S1612, whereas Iuchi et al (2002)
delineated two regions of loss to 1p34–p35 (B5.7Mb) and
1p36.1–p36.2 (B12Mb). These deletion regions do overlap and
may be refined to three loci: 1p36.3 (between D1S468 and D1S253
of B2.9Mb), 1p36.1 (between D1S482 and D1S1676 of 1.4Mb) and
1p34.3–p35 (between D1S247 and D1S496 of 4.4Mb) (Figure 1).
The identification of multiple deletion regions suggests that there
is more than one tumour suppressor gene on the 1p arm. The
possibility of multiple tumour suppressor loci on 1p has also been
suggested from studies of other tumour types such as meningio-
mas (Bello et al, 2000b). Two candidate genes, CDKN2C (1p32.3)
and hRAD54 (1p34.1–p33) were evaluated for their involvement in
OT. Somatic mutation and homozygous deletion of CDKN2C was
detected in 2–5% anaplastic oligodendrogliomas, suggesting
alteration of this gene is involved in progression of a subset of
tumours (Husemann et al, 1999; Pohl et al, 1999; He et al, 2000).
No base alterations were, however, found in hRAD54 (Bello et al,
2000a).
Recent studies have also demonstrated that allelic loss of 1p is
closely associated with chemosensitivity and better prognosis in
patients with anaplastic oligodendrogliomas (Cairncross et al,
1998; Ino et al, 2001). Thus, investigation into the basis of 1p loss
would unveil not only the pathogenesis of OT, but might also
provide insights into the genetic origin of these clinical responses.
In this study, we reported the refinement of one of the critical
deletion regions in OT to 1p36.31–36.32 and the mapping of two
contiguous minimally deleted regions, in which there are only
eight genes annotated.
MATERIALS AND METHODS
Tumour specimens and DNA extraction
A cohort of 52 OTs, including 22 oligodendrogliomas (WHO grade
II), 14 anaplastic oligodendrogliomas (WHO grade III), 13
oligoastrocytomas (WHO grade II) and three anaplastic oligoas-
trocytomas (WHO grade III), and their corresponding blood
samples were obtained from Prince of Wales Hospital, Hong Kong
and Hua Shan Hospital, Shanghai, China. The OTs were classified
according to the current WHO Classification of Tumours of
Nervous System (Reifenberger et al, 2000). Histological assessment
of tissue sections confirmed a tumour cell content of at least 80%
in all samples. The average age of patients was 40.8715.3 years
(range, 8–74) and the male/female ratio was 1.4:1.
DNA was prepared from tissue and blood specimens using the
conventional proteinase K digestion and phenol/chloroform
extraction method. DNA extracted from blood leukocytes was
used as constitutional control.
Microsatellite analysis
A total of 30 microsatellite loci, located on chromosome arms 1p,
1q and 19q, were investigated for loss of heterozygosity (LOH)
according to reported protocol (Tong et al, 2001). In all, 26
polymorphic markers map to 1p arm (D1S171, D1S468, D1S2845,
D1S2893, D1S2660, D1S1608, D1S2132, D1S2795, D1S2870,
D1S1646, D1S1612, D1S2667, D1S2647, D1S482, D1S470, D1S496,
D1S2743, D1S2724, D1S2752, D1S473, D1S1665, D1S2807, D1S188,
D1S2808, D1S2695 and D1S514), two markers map to 1q arm
(D1S215 and D1S2625) and two markers locate to chromosome
19q (D19S219 and D19S412). These markers were labelled either
with fluorochrome FAM or HEX (Proligo, Singapore). Briefly,
polymerase chain reaction (PCR) was performed in a final volume
of 5ml containing 50–100ng of DNA, 10mM Tris-HCl (pH 8.3),
50mM KCl, 2.5mM MgCl2, 0.2mM deoxyribonucleoside tripho-
sphates, 0.5U of AmpliTaq Gold DNA polymerase (Applied
Biosystems, Foster City, USA), and 0.4mM of each primer. The
PCR commenced with an enzyme activation step at 951C for
10min, 40 cycles of 941C for 1min, 55–601C for 1min and 721C for
1min, and finalised with an elongation step at 721C for 10min.
PCR products of multiple markers were pooled and electrophor-
esed in denaturing 4% polyacrylamide gels using an ABI Prism 377
automated DNA sequencer (Applied Biosystems). The data
collected were analysed using GeneScan Analysis software version
3.1 (Applied Biosystems). Allelic imbalance was defined by
calculating the allelic ratio of both normal (N) and tumour (T)
DNA, based on the formula of (N2/N1)/(T2/T1), where N2 or T2
represents the peak height of the longer allele and N1 or T1
represents the peak height of the shorter allele. LOH was inferred
when the allelic ratio was greater than 1.5 or smaller than 0.5,
representing loss of the shorter or longer allele, respectively.
FISH
Dual-colour FISH analysis was performed on formalin-fixed
paraffin-embedded tissue sections as reported with modification
(Jenkins et al, 1997). Section of 5-mm thickness were deparaffi-
nised, dehydrated, treated with sodium thiocyanate at 801C for
10min, digested in pepsin solution (5mgml
 1 in 0.2 N HCl) for
20–30min, rinsed in phosphate-buffered saline and dehydrated.
The sections were then treated with microwave (600W) in citrate
buffer (pH 6.0) for 10min, baked at 801C for 30min and subjected
to hybridisation.
Seven bacterial artificial chromosomes (BACs) or bacteriophage
P1-derived artificial chromosomes (PACs) were labelled to
generate locus-specific FISH probes. These included six target
probes for 1p arm and one reference probe for 1q32 (BAC clone
RP11-79I9 encompassing the marker STSG28964). The genomic
clones were purchased from Invitrogen Corporation (Carlsbad,
Figure 1 Deletion mapping studies of chromosomal arm 1p in OTs. (A)
Reifenberger et al (1994); (B) Bello et al (1995); (C) Zhu et al (1998b); (D)
Husemann et al (1999); (E) Smith et al (1999); (F) Iuchi et al (2002); (G)
current study. Striped bars represent minimally deleted regions identified in
each study.
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yUSA). DNA was labelled by nick-translation in a reaction
containing 100mM Tris-HCl (pH 7.5), 10mM MgCl2, 0.01% bovine
serum albumin, 0.1mM dATP, 0.1mM dCTP, 0.1mM dGTP, 0.1nM
dTTP, 0.1nM b-mercaptoethanol, 0.03U DNase I, 20U of DNA
polymerase I, and 0.85nmol of digoxigenin-1-dUTP (for target
probe) or 1.9nmol of biotin-16-dUTP (for reference probe) (Roche
Diagnostics Ltd., Hong Kong) at 151C for 25–45min. The labelled
probes were mixed with fish sperm and Cot-1 DNA in Hybrisol VI
solution (Appligene Oncor, Illkirch Graffenstaden, France),
denatured and applied onto sections. Hybridisation was carried
out at 371C overnight. Sections were washed with 1.5 M urea/1 
saline sodium citrate (SSC) at 451C for 30min, 2  SSC at 451C for
15min, treated with either antidigoxigenin-rhodamine antibody
(Sigma) or avidin conjugated-fluorescein isothiocyanate (Vector
Laboratories, Burlingame, USA) at 371C for 1.5h, washed in
phosphate-buffered saline detergent (Appligene Oncor), and
counterstained with Vectashield mounting medium with anti-fade
solution of 4,6-diamidino-2phenylindole (DAPI; Vector Labora-
tories).
Sections were viewed under a Zeiss Axioplan microscope and
images of rhodamine, FITC and DAPI were captured through a
triple-pass filter by a cooled charge-coupled device. A total of 200
nonoverlapping tumour nuclei were counted on each section. A
sample was considered having deletion of 1p locus when more
than 70% of counted nuclei exhibited one target signal (red) and
two reference signals (green).
Statistical analysis
Statistical analysis was performed using the software SPSS 10.0.
The correlation between two parameters was evaluated by w
2-test
or Fisher’s exact test, whichever was appropriate. An obtained P-
value less than 0.05 (two-sided) was considered statistical
significant.
RESULTS
Deletion mapping on chromosome 1p
To localise tumour suppressor loci on the short arm of
chromosome 1 in OTs, we carried out a deletion mapping study
across the entire 1p arm using microsatellite analysis. A series of
25 OTs were investigated for LOH at 19 microsatellite loci, spacing
at an average interval of 7Mb on the 1p arm. Each tumour showed
informativeness in at least seven markers. Overall, 15 (60%)
tumours demonstrated LOH in at least one marker, with 14 of
them showing LOH at all informative markers tested suggesting
that these tumours had lost a copy of the entire or most of 1p arm.
One tumour (A18) showed LOH at D1S468 and its juxtaposed
marker D1S2795, both of which map to the telomeric end of
1p36.3, but retained heterozygosity at all informative markers
centromeric to D1S2795 (Figure 2). This deletion segment lies in
the overlapped region of loss defined by Smith et al (1999) and
Husemann et al (1999), indicating that 1p36.3 is a critical region
involved in OT development. Since tumours with small chromo-
somal deletion are useful in delineation of tumour suppressor loci,
we subsequently characterised another series of OTs focusing
specifically at the 1p36.3 region with an aim to obtain additional
cases harbouring interstitial deletion. We evaluated the allelic
status of a total of nine (with seven additional new markers)
polymorphic markers on 1p36.3 in a second series of 27 OTs and
also in those tumours of the first series that showed small terminal
deletion (i.e. case A18) or no LOH. The average interval between
these nine markers is 0.46Mb. In the second series, each tumour
showed informativeness in at least three markers. Totally, 17 (63%)
OTs demonstrated LOH in at least one marker, with 13 of them
showing LOH at all informative markers. Four tumours (B9, B14,
B26 and B27) exhibited LOH patterns suggestive of interstitial
deletion. Cases B9, B14 and B26 lost heterozygosity at single
marker, D1S2660 or D1S2845, while retaining balanced alleles at
other informative loci. B27 showed LOH at two contiguous
markers, D1S2660 and D1S1608, and maintained allelic balance
at D1S2795, which is 0.69Mb proximal to D1S1608. Other markers
were noninformative in this tumour. In addition, our finer
mapping has identified one more tumour (A19) with interstitial
deletion from the initial set of tumours that showed no LOH. A19
had lost heterozygosity at D1S2845 on 1p. Surprisingly, A18 which
initially displayed a telomeric deletion at 1p showed a zebra LOH
pattern upon finer mapping. LOH was demonstrated at distal
markers D1S171 and D1S468 and at proximal markers from
D1S1608 to D1S2795, while allelic balanced markers were detected
between these two regions and centromeric to D1S2795. This result
suggests that A18 harbours two interstitial deletions on 1p36.3.
Figure 2 Summarised results of microsatellite analysis of 52 OTs examined. Cytoband and physical distance of microsatellite markers were derived from
current reference human genome sequence (Build 34). The asterisks represent markers examined in the first round of microsatellite analysis. Filled
circle¼LOH; open circle¼retention of heterozygosity;  ¼noninformative.
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oligodendrogliomas, 11 out of 14 (79%) anaplastic oligodendro-
gliomas, six out of 13 (46%) of oligoastrocytomas, and one out of
three (33%) anaplastic oligoastrocytomas. Tumours with inter-
stitial deletion on 1p36.3 constitute 12% (six out of 52) of all OTs
examined.
Determination of deletion breakpoints on 1p36.3
We then employed an independent assay, interphase FISH, to
verify the allelic status and to determine the deletion breakpoints
in tumours that showed interstitial deletion. Four cases (A18, A19,
B9 and B14), for which tissues were available, were subjected to
FISH. Representative results of FISH are shown in Figure 3.
Tumours were scored as having LOH when more than 70% of
counted nuclei showed single target signal and two reference
signals. Figure 4 summarises the allelic status, determined by both
microsatellite and FISH analyses, of six OTs that showed
interstitial deletion at 1p36.3. Concordant results were obtained
for both techniques. Moreover, FISH revealed the allelic status of
six more markers among the four tumours examined. Based on
these data, two minimally deleted regions (MDRs) are delineated.
MDR1 maps to a region of 0.76Mb, defined by D1S468 and
D1S2845, and MDR2 locates to an interval of 0.41Mb, bound by
D1S2893 and D1S1608.
Genes annotated in MDRs
Based on the latest version of reference human genome sequence
(Build 34, July 2003 freeze) the MDRs are covered by two sequence
contigs (NT_004321 and NT_004547) with a gap of suggested size
of 50kb between these contigs. MDR1 starts from D1S468, which
locates about 230kb to the proximal end of NT_004321, spans over
the sequence gap and ends at D1S2845, which is 480kb from the
distal end of NT_004547, whereas MDR2 lies in NT_004547. There
are seven annotated genes clustered at the distal region of MDR1
on NT_004321 (Table 1). However, in a genomic interval of about
1Mb covering the proximal region of MDR1 to end of MDR2, there
is only one single gene identified, SHREW1.
Allelic statuses of 1q and 19q
Two loci, D1S215 (1q25.2) and D1S2625 (1q31.2), were investigated
for LOH on 1q arm. All tumours except case B24 were informative
at either or both markers. Three tumours (A16, B1 and B7) had lost
heterozygosity at both markers on 1q and also at all informative
markers on 1p, suggesting that the entire chromosome was lost.
Allelic loss of both 1q markers was also observed in tumour A19,
Figure 3 Representative results of microsatellite and interphase FISH
analyses of case A18. Microsatellite markers are indicated on left with
corresponding BAC or PAC clones containing such markers in parentheses.
Concordant results are obtained for both techniques. Of note is that FISH
reveals allelic loss at the noninformative locus D1S2660. Allelic loss (AL) in
microsatellite analysis is indicated by arrowhead and is represented by one
red (target) signal and two green (chromosome 1 centromere) signals in
FISH. Allelic retention (AR) is indicated by the presence of both alleles in
microsatellite analysis and is represented by two red and two green signals.
T¼tumour; B¼tumour-matched blood.
Microsatellite
marker
Physical
distance
(Mb)
BAC/PAC
clone
Case number/tumour subtype
B26 A19
OA OA OA O O O
B14 A18 B27 B9
D1S171
D1S468
D1S2845
D1S2895
D1S2660
D1S1608
D1S2132
D1S2795
D1S2870 5.99
5.27
4.81
4.67
4.48
4.26
4.13
3.37
2.41
RP11-62M23
RP11-28E15
RP1-37J18
RP3-426F10
RP5-1096P7
RP3-491M17
—
—
—
—
—
—— —
—
—
—
—
—
—
— —
* *
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
MDR1
MDR2
0.41 Mb
0.76 Mb
Figure 4 Delineation of MDRs on 1p36.3 in OTs by combined microsatellite and FISH analyses. FISH revealed the allelic status of six noninformative
polymorphic markers (D1S2893, D1S2660 and D1S1608 in A19; D1S468 in B14; D1S2660 in A18; and D1S2893 in B9). The solid bars represent MDRs.
O¼oligodendroglioma WHO grade II; OA¼oligoastrocytoma WHO grade II; filled circle¼LOH; open circle¼retention of heterozygosity; –
¼noninformative; * allelic status confirmed or revealed by FISH.
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heterozygosity at distal marker D1S2625 but maintained allelic
balance at D1S215, whereas A25 showed LOH at D1S2625 and was
noninformative at D1S215. Together, six out of 51 (12%)
informative OTs exhibited LOH on 1q.
Two markers, D19S219 and D19S412, which are 1.02Mb apart
and locate in the common region of deletion on 19q13.3 were
investigated for allelic loss. Out of 51, 33 (65%) informative
tumours exhibited LOH in at least one of the 19q markers. In all,
10 tumours (A2, A5, A11, A18, A19, A22, A23, B13, B26 and B27)
had lost heterozygosity at either marker but maintained allelic
balance at the other marker on 19q.
Taken together, 29 out of 51 (57%) informative tumours
exhibited LOH of at least one marker on both 1p and 19q. Three
tumours (B6, B17 and B14) had 1p LOH in the absence of
detectable 19q LOH, whereas four tumours (A9, A22, B10 and B20)
exhibited 19q LOH but no 1p LOH.
Statistical analysis
The 1p and 19q allelic status was correlated with clinicopatholo-
gical parameters. 1p LOH was found to be closely associated with
19q LOH in OTs (Po0.0001). No statistical significance was
observed between 1p LOH, 19q LOH or combined 1p/19q LOH and
patient’s gender, tumour type or grade. All six OTs with interstitial
deletion on 1p36.3 were of WHO grade II, but only a trend was
seen between interstitial deletion and tumour grade (P¼0.065).
DISCUSSION
Recurrent deletion of chromosome 1p in OTs strongly implies the
presence of tumour suppressor gene(s) on this chromosome arm.
With an aim to isolate the tumour suppressor gene by positional
cloning approach, we set out to map the minimally deleted regions
on the 1p arm. A series of 52 OTs were examined for allelic
deletion by two rounds of microsatellite analysis followed by
confirmation with FISH. Six tumours were found to harbour small
interstitial deletion specifically on 1p36.3. Previous deletion
mapping studies had revealed a few OTs with interstitial deletion
on 1p, thus hindering a precise mapping of the critical deletion
region (Husemann et al, 1999; Smith et al, 1999). This was likely
due to the limited number of markers examined and to the wider
genetic spacing of these markers. By examining more closely
spaced markers on 1p36 in our microsatellite analysis, we were
able to detect interstitial deletion in 12% of our tumour series. The
proportion of tumours with interstitial deletion on 1p is likely to
be an underestimation, as other previously defined deletion
regions were not subject to high-resolution mapping as in this
study. The small overlapping intervals on 1p36.3 have allowed us
to delineate two contiguous MDRs, which fall in the overlapped
region of deletion defined by Smith et al (1999) and Husemann
et al (1999), providing further evidence that the 1p36.3 region is
involved in tumorigenesis of OTs. Moreover, our deletion mapping
study has narrowed down the critical deletion region on 1p36.3 to
B1.2Mb. This genomic region has been sequenced almost to
entirety with a small sequence gap, for which no genomic clones
are available. There are eight genes annotated in the MDRs
(Table 1). Of these genes, only TP73, DFFB and SHREW1 have
been studied previously.
The TP73 gene encodes product that shares significant
structural and functional homology with the p53 tumour
suppressor, raising the possibility that p73 might be a putative
tumour suppressor (reviewed in Melino et al, 2002). Indeed,
functional studies have revealed that p73 has antiproliferative and
proapoptotic activity, independent of p53 status (Zhu et al, 1998a;
Yuan et al, 1999). However, unlike TP53, somatic mutation of TP73
in human cancer is very rare (Mai et al, 1998; Alonso et al, 2001;
Dong et al, 2002; Melino et al, 2002), suggesting that p73 does not
act as a classical Knudson-type tumour suppressor. When
transcript levels were examined, TP73 was found to be over-
expressed in a variety of tumours (Tannapfel et al, 1999; Zaika et al,
1999), but its expression is reduced or absent in certain
haematological malignancies (Corn et al, 1999; Kawano et al,
1999). Such downregulation of transcription is attributed to
promoter hypermethylation (Corn et al, 1999; Kawano et al,
1999). In OTs, promoter hypermethylation of TP73 is detectable in
8–24% of tumours and anaplastic tumours are more common to
harbour such aberration (Dong et al, 2001; Watanabe et al, 2002;
Alonso et al, 2003). The TP73 methylation status has also been
associated with decreased level of TP73 transcript (Dong et al,
2002). Taken together, these data suggest that p73 is involved in a
subset of OTs. However, the recent discovery of N-terminal
truncated isoforms of p73, namely DNp73, has provided new
insights into the role of p73 plays in tumorigenesis. Functional
studies showed that DNp73 is a transdominant inhibitor of wild-
type p53 and p73 by counteracting their target gene transactiva-
tion, apoptosis and growth suppression and is able to immortalise
primary mouse embryo fibroblasts in vitro (Grob et al, 2001;
Nakagawa et al, 2002; Stiewe et al, 2002; Petrenko et al, 2003).
These data demonstrate that DNp73 acts as an oncogene and has
opposing activity of p73. Given the diverse function of p73
Table 1 A list of annotated genes mapped between D1S468 and D1S1608 on chromosome 1p36.3
Locus Gene
a Accession no. Domain
b Biological function
D1S468
TP73 NM_005427 p53 Transactivates p53 target genes, suppresses cell proliferation and induces apoptosis
Sterile alpha motif N-terminally truncated isoforms have anti-apoptotic functions
KIAA0495 AB007964 Unknown Hypothetical protein with unknown function
FLJ32825 NM_152492 Chromosome segregation ATPase Hypothetical protein with unknown function
KIAA1185 NM_020710 Leucine-rich repeat Hypothetical protein with unknown function
Phenylalanyl-tRNA synthetase
KJAA0562 NM_014704 Unknown Hypothetical protein with unknown function
DFFB NM_004402 CIDE-N domain Involved in both DNA fragmentation and chromatin condensation during apoptosis
LOC339448 XM_290902 Unknown Hypothetical protein with unknown function
D1S2845
D1S2893
D1S2660
SHREW1 NM_018836 Transmembrane Binds to E-cadherin and b-catenin in adherens junctions in polarised epithelial cells
D1S1608
aBased on reference human genome sequence Build 34.
bBased on LocusLink (http://www.ncbi.nlm.nih.gov/LocusLink) and InterProScan (http://www.ebi.ac.uk/interpro).
1p36.3 deletion in oligodendroglial tumours
Z Dong et al
1109
British Journal of Cancer (2004) 91(6), 1105–1111 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yisoforms, it is thus of paramount importance to resolve the
functional contribution of each isoform toward cancer develop-
ment.
DFFB is the other known gene identified in MDR1. It encodes the
caspase-activated DNase and is responsible for degradation of
chromosomal DNA during apoptosis. Its gene product is com-
plexed with an inhibitor encoded by DFFA in vivo. Upon apoptosis
induction, caspase cleaves the inhibitor and releases DFFB from the
complex to enter into nuclei to degrade chromosomal DNA (Nagase
et al, 2003). No somatic mutations of DFFB were detected in 41
neuroblastomas examined (Judson et al, 2000). However, aberrant
DFFB transcripts resulting from splicing have been reported in
hepatocellular carcinoma (Hsieh et al, 2003).
SHREW1 appears to be the single gene located in MDR2.
Recently, the cDNA of SHREW1 was isolated from invasive
endometriotic cells (Bharti et al, 2004). This gene encodes a
B48kDa transmembrane protein, with its carboxy terminus being
cytoplasmic, and does not belong to any protein family. Ectopic
expression of SHREW1 in polarised epithelial cells showed that
shrew1 protein colocalised with E-cadherin in adherens junctions,
probably via binding of b-catenin. However, in nonpolarised
invasive epithelial cells, shrew1 bound neither to N-cadherin and
b-catenin (Bharti et al, 2004). E-cadherin is generally not
expressed in brain tumours, except in benign meningiomas
(Schwechheimer et al, 1998), whereas N-cadherin and b-catenin
are detectable at cell–cell junctions in malignant astrocytic
tumours (Utsuki et al, 2002). The N-cadherin and b-catenin status
in OT is not known. Further investigation of SHREW1 function
may shed light on the role of this gene plays in cancer development
and its involvement in invasion.
In conclusion, our deletion mapping study has refined one of the
candidate tumour suppressor loci on chromosome arms 1p in OTs.
Two contiguous MDRs are delineated from a small interval on
1p36.3, between D1S468 and D1S1608, which contain only eight
known and novel genes. These candidate genes are currently under
investigation for their involvement in OTs.
Note added in proof
A recent report by Felsberg et al (Brain Pathology 2004;14:
121–130) marked one of the commonly deleted regions to 1p36.31-
pter in oligodendroglial tumours. Their results are in line with our
findings.
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